Thirteen months instead of six—time to spend with family, time to settle affairs
Por décadas, el cáncer de páncreas ha sido sinónimo de sentencia inapelable: silencioso en su avance, letal en su desenlace. En junio de 2026, investigadores presentaron en Chicago evidencia de que un nuevo fármaco oral llamado daraxonrasib casi duplicó el tiempo de supervivencia en pacientes con enfermedad avanzada, extendiendo la mediana de vida de seis a trece meses. El hallazgo, publicado simultáneamente en el New England Journal of Medicine, no promete una cura, pero representa algo que esta enfermedad rara vez ha concedido: tiempo.
- El cáncer de páncreas metastásico mata en un promedio de tres meses sin tratamiento, convirtiendo cada avance terapéutico en una carrera contra un reloj implacable.
- Daraxonrasib logró una reducción del 60% en mortalidad en un ensayo de fase tres con 500 pacientes, cifra que arrancó aplausos en el congreso más importante de oncología del mundo.
- El fármaco amplía el blanco terapéutico al atacar la mayoría de las variantes de mutaciones RAS, presentes en el 90% de los casos, superando las limitaciones de tratamientos anteriores.
- Los investigadores advierten que el medicamento no es curativo, pero reconocen que marca un antes y un después en una enfermedad que ha resistido décadas de intentos fallidos.
- Para los pacientes, la diferencia entre seis y trece meses no es estadística: es tiempo real con sus familias, tiempo para cerrar ciclos, tiempo para esperar lo que venga después.
El cáncer de páncreas mata con una eficiencia brutal. Solo el 13% de los pacientes sobrevive cinco años tras el diagnóstico, y la enfermedad suele anunciarse demasiado tarde: cuando aparecen los síntomas —dolor abdominal, pérdida de peso, ictericia—, el tumor ya se ha diseminado. Sin tratamiento, los pacientes con enfermedad en estadio 4 tienen apenas tres meses de vida.
En junio de 2026, durante la conferencia anual de la Sociedad Americana de Oncología Clínica en Chicago, investigadores presentaron resultados que cambiaron el tono de la conversación. Un nuevo fármaco oral llamado daraxonrasib casi duplicó la supervivencia en pacientes con cáncer de páncreas avanzado: quienes lo recibieron vivieron una mediana de 13 meses, frente a los seis meses del grupo con quimioterapia estándar. La reducción de mortalidad del 60% fue recibida con aplausos y publicada simultáneamente en el New England Journal of Medicine.
El mecanismo del fármaco se inscribe en la medicina de precisión: daraxonrasib ataca las mutaciones del gen RAS, presentes en el 90% de los cánceres de páncreas, y lo hace con un espectro más amplio que terapias anteriores, cubriendo la mayoría de las variantes conocidas de esa mutación.
Zev Wainberg, de UCLA y co-líder del ensayo, fue cuidadoso al interpretar los resultados. El fármaco no cura el cáncer de páncreas, subrayó. Pero para una enfermedad que ha sido uniformemente fatal, ver este nivel de beneficio en un ensayo aleatorizado de fase tres es, en sus palabras, 'un cambio de paradigma'. Rachna Shroff, directora de oncología en la Universidad de Arizona, coincidió en que los resultados representan un giro radical para los pacientes con mutaciones KRAS.
Para quienes viven con esta enfermedad, los siete meses adicionales no son un dato abstracto. Son tiempo.
Pancreatic cancer kills with brutal efficiency. Only 13 percent of patients survive five years after diagnosis. The disease spreads quietly, often announcing itself too late—by the time symptoms arrive, the tumor has already metastasized. For decades, oncologists have fought this particular malignancy with limited weapons. But in June 2026, at the annual conference of the American Society of Clinical Oncology in Chicago, researchers presented results that shifted the entire conversation.
A new oral medication called daraxonrasib nearly doubled survival time in patients with advanced pancreatic cancer. In a clinical trial involving 500 patients with metastatic disease, those treated with the drug survived a median of 13 months, compared to six months for patients receiving standard chemotherapy. That's a 60 percent reduction in mortality—a magnitude of benefit that drew applause from thousands of oncologists and simultaneous publication in the New England Journal of Medicine.
The pancreas itself is a small, vulnerable organ tucked deep in the abdomen. It regulates blood sugar and aids digestion. When cancer takes hold there, it doesn't stay confined. The tumor can damage the bile ducts, the gallbladder, the liver. Patients often don't notice until the disease has already spread—abdominal pain that radiates to the ribs or back, appetite vanishing, weight dropping away, skin and eyes turning yellow with jaundice. By then, the prognosis is grim. Without treatment, patients with stage 4 metastatic pancreatic cancer have roughly three months to live.
Daraxonrasib works through precision medicine, a strategy that has transformed cancer treatment over the past decade. Doctors now sequence tumors to identify their genetic mutations, then match drugs to those specific flaws. The pancreatic cancers in 90 percent of cases carry mutations in the RAS gene—a protein that, when mutated, drives uncontrolled cell growth. Previous drugs targeted only certain subtypes of RAS mutations. Daraxonrasib casts a wider net, attacking most of the RAS variants that appear in pancreatic tumors.
Rachna Shroff, who heads hematology and oncology at the University of Arizona Cancer Center, called the results a radical shift for patients carrying KRAS mutations. Zev Wainberg, a researcher at UCLA who co-led the trial, was careful not to overstate what had been achieved. The drug doesn't cure pancreatic cancer, he emphasized. But it represents a genuine turning point for a disease that has resisted treatment for generations. "Seeing this magnitude of benefit in a randomized phase three trial is deeply encouraging," Wainberg said. "This is a paradigm shift for a disease that has been uniformly fatal."
For thousands of patients with advanced pancreatic cancer, the difference between six months and thirteen months is not merely statistical. It is time—time to spend with family, time to settle affairs, time to try other treatments if they emerge. The drug is not a cure. But in a disease where hope has been scarce, it is something.
Notable Quotes
These results represent a radical shift for patients with metastatic pancreatic cancer carrying KRAS mutations— Rachna Shroff, University of Arizona Cancer Center
The drug doesn't cure pancreatic cancer, but it is a very important step forward. Seeing this magnitude of benefit in a randomized phase three trial is deeply encouraging and represents a paradigm shift for this deadly disease— Zev Wainberg, UCLA, co-director of the study
The Hearth Conversation Another angle on the story
Why does pancreatic cancer kill so much faster than other cancers?
It grows silently and spreads before anyone notices. By the time symptoms show up—pain, jaundice, weight loss—the tumor has usually already left the pancreas. You're already in stage 4.
And this new drug, daraxonrasib—it actually works on most pancreatic cancers?
On most of the ones with RAS mutations, yes. That's 90 percent of cases. The trick is that RAS mutations come in many varieties. Old drugs only hit one or two types. This one covers most of them.
Thirteen months instead of six. That's doubling survival. Why hasn't something like this existed before?
Because pancreatic cancer is rare enough that it didn't attract the research money other cancers did. And the biology is genuinely difficult. It took precision medicine—sequencing tumors, understanding their exact mutations—to even make this possible.
Is this a cure?
No. The researchers were clear about that. It extends life, sometimes significantly. But the cancer still wins eventually. What matters is that patients now have more time, and more options to try.
What happens next? Does this drug get approved?
It's already in late-stage trials. The results were strong enough that approval is likely. But access will depend on whether patients can afford it, whether insurance covers it, whether it gets distributed globally or stays in wealthy countries.
So this is a breakthrough, but not the end of the story.
Exactly. It's the first real hope this disease has had in a long time. But hope and access are two different things.